ETRADE Capital Management LLC reduced its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,313 shares of the biopharmaceutical company’s stock after selling 3,777 shares during the period. ETRADE Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,875,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the company. Portfolio Solutions LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $37,000. Gantzert Investment Co. LLC ADV acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. 1 North Wealth Services LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $42,000. Larson Financial Group LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $64,000. Finally, Arlington Partners LLC lifted its holdings in Bristol-Myers Squibb by 40.0% in the fourth quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 73.35% of the company’s stock.
A number of research analysts recently commented on BMY shares. Morgan Stanley set a $54.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, December 20th. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. Societe Generale upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a report on Tuesday, January 15th. BMO Capital Markets reiterated a “buy” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, February 19th. Finally, Bank of America set a $53.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Friday, January 25th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $59.40.
Shares of NYSE BMY opened at $49.96 on Friday. The company has a market capitalization of $80.88 billion, a price-to-earnings ratio of 12.55, a PEG ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. Bristol-Myers Squibb Co has a 52-week low of $44.30 and a 52-week high of $67.44.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. The company had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.68 earnings per share. Analysts predict that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: QQQ ETF
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.